Todas las fotos(1)

Key Documents

I0361000

Ipratropium bromide impurity B

Name: Ipratropium bromide impurity B
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Sinónimos:

(1R,3r,5S,8s)-3-[[(2RS)-3-Hydroxy-2-phenylpropanoyl]oxy]-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):

C₂₀H₃₀BrNO₃

Número de CAS:

58073-59-9

Peso molecular:

412.36

Código UNSPSC:

41116107

NACRES:

NA.24

Productos recomendados

Slide 1 of 10

1 of 10

Y0000276

Ipratropium impurity A

BP930

Ciprofloxacin impurity standard

USP

1347529

Ipratropium bromide Related Compound B

USP

1347530

Ipratropium bromide Related Compound C

X0101000

Xylometazoline impurity A

BP626

8s-Isopropyl-3β-hydroxytropanium bromide

Supelco

PHR3017

Ipratropium Bromide Related Compound A

Y0000757

(−)-Riboflavina

USP

1347518

Ipratropium bromide Related Compound A

USP

1492266

Palonosetron Related Compound E

grado

pharmaceutical primary standard

familia API

ipratropium

fabricante / nombre comercial

EDQM

aplicaciones

pharmaceutical (small molecule)

formato

neat

temp. de almacenamiento

2-8°C

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Materiales de referencia analítica para control de calidad farmacéutico

Patrones de las farmacopeas y de los institutos metrológicos

Descripción general

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicación

Ipratropium bromide impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Envase

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Otras notas

Sales restrictions may apply.

Producto relacionado

Referencia del producto

Descripción

Precios

Palabra de señalización

Warning

Frases de peligro

H302

Consejos de prudencia

P264 - P270 - P301 + P312 - P501

Clasificaciones de peligro

Acute Tox. 4 Oral

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

The effect of bronchodilators administered via aerochamber or a nebulizer on inspiratory lung function parameters.

S K Ramlal et al.

Respiratory medicine, 107(9), 1393-1399 (2013-06-19)

In chronic obstructive pulmonary disease (COPD) the clinical efficacy of bronchodilator therapy delivered via a nebulizer versus an aerochamber on FEV1 is controversial. No studies comparing changes in inspiratory pulmonary function parameters (ILPs) using these inhaler devices are currently available.

Evaluation of lung function and deposition of aerosolized bronchodilators carried by heliox associated with positive expiratory pressure in stable asthmatics: a randomized clinical trial.

Luciana Alcoforado et al.

Respiratory medicine, 107(8), 1178-1185 (2013-05-15)

While administration of medical aerosols with heliox and positive airway pressure are both used clinically to improve aerosol delivery, few studies have differentiated their separate roles in treatment of asthmatics. The aim of this randomized, double blinded study is to

Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD.

Virginia Norris et al.

Pulmonary pharmacology & therapeutics, 26(5), 574-580 (2013-03-26)

There are few data on the bronchodilatory effects of adding short-acting bronchodilators (SABA) to maintenance, long-acting bronchodilator therapy. This study assessed the additional bronchodilation and safety of adding supratherapeutic doses of salbutamol (SALB) or ipratropium bromide (IPR) to the novel

Intranasal ipratropium bromide for the common cold.

Zaina H AlBalawi et al.

The Cochrane database of systematic reviews, 6(6), CD008231-CD008231 (2013-06-21)

The common cold is one of the most common illnesses in humans and constitutes an economic burden both in terms of productivity and expenditure for treatment. There is no proven cure for the common cold and symptomatic relief is the

Predictors of adherence to inhaled medications.

John C Huetsch et al.

Journal of general internal medicine, 28(6), 759-759 (2013-03-27)

Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico